News Release

Mallinckrodt Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

ST. LOUIS--(BUSINESS WIRE)--Sep. 3, 2013-- Mallinckrodt (NYSE: MNK), a leading global specialty pharmaceuticals and global medical imaging company, will present at the Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2013. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the Company in a session scheduled to begin at 1:15 PM EDT.

A live audio webcast of the presentation can be accessed at Mallinckrodt’s website,, in the Investor Relations tab.


Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents. The Company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 50 countries and distribution in approximately 40 countries. The Company’s 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit

Source: Mallinckrodt

John Moten, 314-654-6650
Vice President, Investor Relations
Lynn Phillips, 314-654-3263
Manager, Media Relations
Meredith Fischer, 314-654-6595
Senior Vice President, Communications